Navigation Links
GeneGo Awarded NIH Grant to Develop Pharmacogenomics Software Suite
Date:7/28/2009

ST. JOSEPH, Mich., July 28 /PRNewswire/ -- GeneGo, Inc., the leading systems biology company, today announced that it has been awarded a grant to develop an integrated systems pharmacology platform for pharmacogenomic research. The SBIR grant, funded through the innovations in biomedical computational science and technology initiative, will be used to develop a database and systems biology tool-set specifically designed for the study of mutations and sequence heterogeneity in human genes and their controlling regions, as well as the biological consequences of sequence variations on disease susceptibility and drug response.

"Genome-wide association studies and next-generation resequencing projects are already generating vast amounts of data on genetic factors contributing to disease susceptibility and variability in the pharmacological and toxicological effects of drugs," said Richard Brennan, Director of Toxicology at GeneGo and PI on the grant. "What is lacking are powerful tools for researchers to be able to link these sequence variations to the specific mechanisms and biological pathways driving idiosyncratic outcomes. The product will smooth the progress of personalized medicine by facilitating the application of personal genetic profiling to identify optimal therapeutic strategies."

"Receiving such a prestigious grant award is another example of the cutting edge research at GeneGo that sets us apart from other companies," said Julie Bryant, GeneGo's VP of Business Development. "It allows us to develop novel tools and databases to help our customers mine important content from the literature, analyze their data and test their hypotheses."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.4(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.4(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GeneGo and OmicSoft Announce Integration
2. A*STARs Singapore Immunology Network Is the First GeneGo Center of Excellence in Asia
3. KineMed Licenses GeneGos MetaCore
4. GeneGos First Customer in Hong Kong; The Chinese University of Hong Kong
5. GeneGo Rolls out MetaMiner Cystic Fibrosis - the First Disease-Specific Software Platform to Advance Drug Discovery
6. Elan Pharmaceuticals Joins GeneGos MetaTox Consortium
7. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
8. GeneGo Licenses MetaCore Data Analysis Suite to AVEO Pharmaceuticals
9. URI awarded $13 million grant to develop vaccines for emerging infectious diseases
10. Resurrection Health Care Primary Stroke Care Programs Awarded Accreditation from Joint Commission
11. LifeSpan Treadmill Awarded BEST TREADMILL by Health Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... May 28, 2016 , ... May 26, 2016- In ... Arts Fighting Challenge with theme event of “K Warriors” on June 4, 2016 at ... , The event is sponsored and hosted by Shaolin Institute and sanctioned by ...
(Date:5/27/2016)... , ... May 27, 2016 , ... Two director-level employees ... YWCA Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen ... For this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) ...
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... ... casual readers, this installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven ... tech within the industry, from leading advocates, associations and industry leaders such as ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... students studying complementary medicine. Allison Outerbridge is this year’s Life University ... May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge is approaching ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, ... respirators, according to court documents and SEC filings. A jury has returned ... v. American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
(Date:5/26/2016)... 2016 TARE (Transarterial Radio-embolization) ... Savings and Overall Decreased Use of Hospital ... international specialist healthcare company, has today announced the ... Meeting of ISPOR (International Society for Pharmacoeconomics and ... (HCC) using yttrium-90 glass microspheres is associated with ...
(Date:5/25/2016)... HILDEN , Deutschland und GERMANTOWN, ... Zusammenarbeit mit Therawis bedient ... Entscheidungen bei Brustkrebs   QIAGEN N.V. ... QIA) gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung ... prädiktiver Assays für die Onkologie eingegangen zu sein. ...
Breaking Medicine Technology: